-
Article
Open AccessImproved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients
The relevance of blood-based assays to monitor minimal residual disease (MRD) in non-metastatic prostate cancer (PCa) remains unclear. Proving that clinically relevant circulating tumor cells (CTCs) can be det...
-
Article
Open AccessCharacterization of different CTC subpopulations in non-small cell lung cancer
Circulating tumour cells (CTCs) serve as valuable biomarkers. However, EpCAM positive CTCs are less frequently detected in NSCLC patients compared to other epithelial tumours. First, EpCAM protein expression w...
-
Article
Open AccessA Versatile Microarray Platform for Capturing Rare Cells
Analyses of rare events occurring at extremely low frequencies in body fluids are still challenging. We established a versatile microarray-based platform able to capture single target cells from large backgrou...
-
Chapter
Pathogenesis of Minimal Residual Disease: CTCs as Novel Biomarkers in Cancer Disease
The use of biomarkers in cancer medicine provides great opportunities for improving the management of patients by enhancing the efficiency of detection or by monitoring the efficacy of systemic (neo)adjuvant t...
-
Article
Circulating tumor cells as therapy-related biomarkers in cancer patients
Carcinomas (tumors of epithelial origin) are responsible for most of all new cancers in the industrialized countries. Due to the high mortality rate caused by the metastatic spread of aggressive cancer cells, ...
-
Article
Open AccessCirculating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
Circulating tumour cells (CTCs) have shown prognostic relevance in metastatic breast, prostate, colon and pancreatic cancer. For further development of CTCs as a biomarker, we compared the performance of diffe...
